BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24198391)

  • 1. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.
    Liu Y; Hu X; Liu H; Bu L; Ma X; Cheng K; Li J; Tian M; Zhang H; Cheng Z
    J Nucl Med; 2013 Dec; 54(12):2132-8. PubMed ID: 24198391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [
    Kálmán-Szabó I; Szabó JP; Arató V; Dénes N; Opposits G; Jószai I; Kertész I; Képes Z; Fekete A; Szikra D; Hajdu I; Trencsényi G
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
    Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.
    Varasteh Z; Aberg O; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Antoni G; Sandström M; Tolmachev V; Orlova A
    PLoS One; 2013; 8(12):e81932. PubMed ID: 24312607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Study on GRPR-Targeted (68)Ga-Probes for PET Imaging of Prostate Cancer.
    Sun Y; Ma X; Zhang Z; Sun Z; Loft M; Ding B; Liu C; Xu L; Yang M; Jiang Y; Liu J; Xiao Y; Cheng Z; Hong X
    Bioconjug Chem; 2016 Aug; 27(8):1857-64. PubMed ID: 27399868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a ⁶⁴Cu‑labeled 1,4,7‑triazacyclononane, 1‑glutaric acid‑4,7 acetic acid (NODAGA)‑galactose‑bombesin analogue as a PET imaging probe in a gastrin‑releasing peptide receptor‑expressing prostate cancer xenograft model.
    Kim MH; Park JA; Woo SK; Lee KC; An GI; Kim BS; Kim KI; Lee TS; Kim CW; Kim KM; Kang JH; Lee YJ
    Int J Oncol; 2015 Mar; 46(3):1159-68. PubMed ID: 25586565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
    Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
    J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
    Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR
    J Nucl Med; 2011 Dec; 52(12):1970-8. PubMed ID: 22080443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
    Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
    Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
    Lears KA; Ferdani R; Liang K; Zheleznyak A; Andrews R; Sherman CD; Achilefu S; Anderson CJ; Rogers BE
    J Nucl Med; 2011 Mar; 52(3):470-7. PubMed ID: 21321264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14).
    Fournier P; Dumulon-Perreault V; Ait-Mohand S; Tremblay S; Bénard F; Lecomte R; Guérin B
    Bioconjug Chem; 2012 Aug; 23(8):1687-93. PubMed ID: 22770480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
    Liu Z; Yan Y; Liu S; Wang F; Chen X
    Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
    Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH
    Peptides; 2015 May; 67():45-54. PubMed ID: 25797109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of peptide-based imaging agents [
    Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
    Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
    Persson M; Liu H; Madsen J; Cheng Z; Kjaer A
    Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
    Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
    J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel
    Lucente E; Liu H; Liu Y; Hu X; Lacivita E; Leopoldo M; Cheng Z
    Bioconjug Chem; 2018 May; 29(5):1595-1604. PubMed ID: 29587479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.